Cingulate Inc (CING) - Cash Funds Volume per Share

Corporate emblem and logo of Cingulate Corp (CING)

Cingulate Inc. maintains a positive image within the ADHD therapy niche, as evidenced by the cash per share data provided in GURU.Markets, where the value 1.55 captures the metric level. The business relies on a precision drug-release system to ensure a stable effect. High scalability potential is driven by intellectual property that enables the mass production of high-cost medications for the global market.

Cingulate Inc. (CING): Cash Funds per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for Cingulate Inc (CING)

- current price and projected stock value:
- cash position and cash flow details:
Summary company analysis:CING (Cingulate Corp)
Core merchandise of Cingulate

Cingulate Inc. is investing in unique CTR technology to develop ADHD medications with protection against generics. These R&D expenditures directly impact the cash balance per share. This metric measures the real value of cash reserves available to each shareholder. Sharp fluctuations in the current cash per share level signal secondary offerings or asset sales. Analyzing this chart allows for the immediate detection of investor equity dilution.